FindTrial
Sign In

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2012-002308-41-FR
Enrollment
Unknown
Registered
2013-05-21
Start date
Unknown
Completion date
Unknown
Last updated
2013-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 14.1 Level: LLT Classification code 10051811 Term: Cerebral lymphoma System Organ Class: 100000004864

Interventions

Trade Name: MYOCET 50mg Product Name: MYOCET Pharmaceutical Form: Lyophilisate and solvent for suspension for injection INN or Proposed INN: Doxorubicin Concentration unit: mg milligram(s) Concentrati

Sponsors

CHRU de Brest
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

France

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026